TrakCel was founded as a joint enterprise between academic spinout AwenID and Biotec Services International, a specialist provider of ultra-low temperature-controlled supply chain management services to the biotechnology industry. TrakCel’s vision was to use the expertise of their founders to create a technology-driven, collection-to-administration supply chain management platform for the orchestration and efficient management of cell and gene therapies at clinical trial and commercial scale.

Success Factor

The TrakCel platform was the first of its kind in the cell and gene therapy industry and significant investment in product development means that TrakCel is one of only a couple of platforms that can cater for three of the major advanced therapies in the autologous therapy, allogeneic therapy and personalised cancer vaccines sector.

The Future

The company will continue to invest heavily into its product development and additional integrations with complimentary service providers will continue to drive demand and increase access of the platform to users internationally. TrakCel has also built a partner ecosystem of connected companies and is regularly running partnership networking events to educate the market on the benefits of an integrated supply chain. It will also be looking to develop its service offering outside of the product in customer service and project consultation.